Medtronic plc. Ordinary Shares (MDT) Financial Statements

Medtronic plc. Ordinary Shares

MDT · NYSE

	FY2026	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019
Total Revenue	$36.36B	$33.54B	$32.36B	$31.23B	$31.69B	$30.12B	$28.91B	$30.56B
Cost of Revenue	$12.72B	$11.63B	$11.22B	$10.72B	$10.14B	$10.48B	$9.42B	$9.15B
Selling, General & Administrative	$11.78B	$10.85B	$10.74B	$10.41B	$10.29B	$10.15B	$10.11B	$10.42B
Operating Income	$6.47B	$5.96B	$5.14B	$5.49B	$5.75B	$4.48B	$4.79B	$6.27B
Interest Expense	$383.00M	$511.00M	$719.00M	$636.00M	$553.00M	$925.00M	$1.09B	$1.44B
Other Income / (Expense)	$384.00M	$402.00M	$412.00M	$515.00M	$318.00M	$336.00M	$356.00M	$373.00M
Income Before Taxes	$6.14B	$5.63B	$4.84B	$5.36B	$5.52B	$3.90B	$4.05B	$5.20B
Provision for Income Taxes	$1.30B	$936.00M	$1.13B	$1.58B	$456.00M	$265.00M	-$751.00M	$547.00M
Net Income	$4.80B	$4.66B	$3.68B	$3.76B	$5.04B	$3.61B	$4.79B	$4.63B
Basic EPS	$3.75	$3.63	$2.77	$2.83	$3.75	$2.68	$3.57	$3.44
Diluted EPS	$3.73	$3.61	$2.76	$2.82	$3.73	$2.66	$3.54	$3.41
Basic Shares Outstanding	1.28B	1.29B	1.33B	1.33B	1.34B	1.34B	1.34B	1.35B
Diluted Shares Outstanding	1.29B	1.29B	1.33B	1.33B	1.35B	1.35B	1.35B	1.36B

Analyst Estimates

Period	Consensus EPS	Low	High	Estimates	Revisions
Apr 2027	$5.94	$5.88	$6.00	12	↑1 ↓0
Apr 2028	$6.38	$6.24	$6.56	10	↑0 ↓0
Apr 2029	$7.03	$6.96	$7.09	2	↑0 ↓0
Apr 2030	$7.47	$7.44	$7.50	2	↑0 ↓0

Forward estimates are the sell-side consensus reported by Nasdaq, not a metir forecast.

Symbol: MDT
Type: Stock
Sector: Health Care
Industry: Biotechnology: Electromedical & Electrotherapeutic Apparatus
Country: North America
Exchange: NYSE

Medtronic plc , headquartered in Galway, Ireland , is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission - to alleviate pain, restore health, and extend life - unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary.

Key Issues

Bullish view

Revenue increased from $33.5 billion to $36.4 billion and net income also rose, to $4.8 billion, showing that higher sales were accompanied by improved earnings.

Bearish view

Net income increased only from $4.7 billion to $4.8 billion while revenue grew by $2.9 billion, suggesting limited earnings conversion from the reported top-line growth.

Analyst Consensus

See all

Buy

27 analysts

$86

Current

—

Low

$96

Average

—

High

Average target implies +12.20% versus the current price.

Earnings History

BeatMissNo estimate

Peers

Vertex Pharmaceuticals IncorporatedVRTX · NASDAQ-GS